Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,987 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Utility and safety of robot-assisted radical cystectomy in older patients with bladder cancer.
Kumada N, Nakane K, Yamada T, Tomioka-Inagawa R, Sugino F, Namiki S, Kawase M, Kawase K, Takeuchi S, Nakai C, Kato D, Takai M, Iinuma K, Tobisawa Y, Koie T. Kumada N, et al. Among authors: yamada t. Minim Invasive Ther Allied Technol. 2023 Dec;32(6):307-313. doi: 10.1080/13645706.2023.2249986. Epub 2023 Aug 22. Minim Invasive Ther Allied Technol. 2023. PMID: 37607213 Review.
Biochemical recurrence after chemohormonal therapy followed by robot-assisted radical prostatectomy in very-high-risk prostate cancer patients.
Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y, Yamada T, Namiki S, Kumada N, Kawase K, Kato D, Takai M, Iinuma K, Tobisawa Y, Ito T, Koie T. Sugino F, et al. Among authors: yamada t. J Robot Surg. 2023 Oct;17(5):2441-2449. doi: 10.1007/s11701-023-01670-3. Epub 2023 Jul 19. J Robot Surg. 2023. PMID: 37466903
Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study.
Yamada T, Nakane K, Enomoto T, Tomioka M, Taniguchi T, Ishida T, Ozawa K, Takagi K, Ito H, Takeuchi S, Kawase M, Kawase K, Kato D, Takai M, Iinuma K, Yokoi S, Nakano M, Koie T. Yamada T, et al. Biomedicines. 2022 Sep 9;10(9):2243. doi: 10.3390/biomedicines10092243. Biomedicines. 2022. PMID: 36140344 Free PMC article.
The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study.
Iinuma K, Yamada T, Kameyama K, Taniguchi T, Kawada K, Ishida T, Nagai S, Enomoto T, Ueda S, Takagi K, Kawase M, Takeuchi S, Kawase K, Kato D, Takai M, Nakane K, Koie T. Iinuma K, et al. Among authors: yamada t. Cancers (Basel). 2023 Feb 2;15(3):947. doi: 10.3390/cancers15030947. Cancers (Basel). 2023. PMID: 36765903 Free PMC article.
Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer.
Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y, Tomioka-Inagawa R, Yamada T, Namiki S, Kumada N, Takeuchi S, Kawase K, Kato D, Takai M, Iinuma K, Tobisawa Y, Koie T. Sugino F, et al. Among authors: yamada t. Life (Basel). 2023 Apr 23;13(5):1072. doi: 10.3390/life13051072. Life (Basel). 2023. PMID: 37240717 Free PMC article.
Case of extragonadal germ cell tumor mimicking left adrenal tumor.
Ito H, Nakane K, Yamada T, Kobayashi K, Miyazaki T, Koie T. Ito H, et al. Among authors: yamada t. Urol Case Rep. 2023 Jun 21;50:102477. doi: 10.1016/j.eucr.2023.102477. eCollection 2023 Sep. Urol Case Rep. 2023. PMID: 37416752 Free PMC article.
11,987 results
You have reached the last available page of results. Please see the User Guide for more information.